Latest Market News

Kinterra Capital has lodged a formal review application against the Takeovers Panel’s earlier ruling involving New World Resources, signaling potential shifts in the ongoing corporate governance saga.

Imugene Limited has launched a A$37.5 million capital raising to advance its promising off-the-shelf CAR T therapy, azer-cel, following encouraging Phase 1b data showing a 75% overall response rate in lymphoma patients.

Imugene Limited has completed a $22.5 million institutional placement and launched a $15 million Share Purchase Plan, both featuring attaching options, to fund its azer-cel clinical program through a pivotal trial in 2026.

Beacon Minerals has confirmed extensive near-surface laterite-hosted gold mineralisation at its Iguana Gold Project, highlighting promising grades for low-cost mining and advancing resource modelling.

Lumos Diagnostics Holdings Limited has had its ASX trading suspension lifted following news of a strategic material agreement, signaling potential growth ahead.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

Anson Resources has successfully implemented a polishing process at its Green River Lithium Project that significantly reduces contaminants in lithium chloride eluate, paving the way for battery-grade lithium carbonate production.

The Federal Court has approved Yumbah Aquaculture’s acquisition of Clean Seas Seafood, setting the stage for a significant consolidation in Australia’s seafood farming sector. Shareholders face a choice between cash or shares as the scheme moves toward implementation.

Caspin Resources has completed the second tranche of its $2.1 million capital raising, issuing shares and free-attaching options approved by shareholders. The move strengthens funding for its diverse Australian mineral projects.

Hawsons Iron Limited has successfully raised $1.91 million through an oversubscribed Share Purchase Plan and a targeted Placement, positioning the company to fast-track key project studies and environmental assessments.

Future Generation Global has reported a strong 20.8% investment portfolio return for the year ending June 2025, prompting an increase in its fully franked interim dividend to 4.0 cents per share. This marks the sixth consecutive year of dividend growth for the ASX-listed investment company.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.